Compounds > myxopyronin b
Page last updated: 2024-10-15

myxopyronin b

Cross-References

ID SourceID
PubMed CID135423114
CHEMBL ID247042
CHEBI ID188570
MeSH IDM0120134

Synonyms (8)

Synonym
carbamic acid, (5-(3-(2,5-dimethyl-1-oxo-2,4-nonadienyl)-4-hydroxy-2-oxo-2h-pyran-6-yl)-1-hexenyl)-, methyl ester, (r-(e,e,e))-
brn 5162839
CHEMBL247042
88192-99-8
CHEBI:188570
methyl n-[(e,5r)-5-[5-[(2e,4e)-2,5-dimethylnona-2,4-dienoyl]-4-hydroxy-6-oxopyran-2-yl]hex-1-enyl]carbamate
4c4 ,
methyl [(1e,5r)-5-{3-[(2e,4e)-2,5-dimethylnona-2,4-dienoyl]-4-hydroxy-2-oxo-2h-pyran-6-yl}hex-1-en-1-yl]carbamate
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aromatic ketoneA ketone in which the carbonyl group is attached to an aromatic ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (29)

Assay IDTitleYearJournalArticle
AID656625Antibacterial activity against kanamycin-resistant,acrAB::Tn903 deficient Escherichia coli SM1411 expressing lacI3, lacZ118, proB, trp, nalA, rpsL in the presence of polymyxin B nonapeptide2011ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
Structure-based ligand design of novel bacterial RNA polymerase inhibitors.
AID310767Antibacterial activity against Staphylococcus aureus2007Bioorganic & medicinal chemistry letters, Dec-15, Volume: 17, Issue:24
Syntheses of novel myxopyronin B analogs as potential inhibitors of bacterial RNA polymerase.
AID727790Inhibition of Escherichia coli RNA polymerase after 1 hr by fluorescence assay2013ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2
Novel hybrid-type antimicrobial agents targeting the switch region of bacterial RNA polymerase.
AID656622Antibacterial activity against Staphylococcus aureus SH1000 expressing rsbU gene in the presence of polymyxin B nonapeptide2011ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
Structure-based ligand design of novel bacterial RNA polymerase inhibitors.
AID776895Antibacterial activity against Pseudomonas aeruginosa PAO12013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Discovery of novel bacterial RNA polymerase inhibitors: pharmacophore-based virtual screening and hit optimization.
AID656618Antibacterial activity against Staphylococcus aureus SH1000 expressing rsbU gene2011ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
Structure-based ligand design of novel bacterial RNA polymerase inhibitors.
AID656623Antibacterial activity against Bacillus subtilis 1S34 in the presence of polymyxin B nonapeptide2011ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
Structure-based ligand design of novel bacterial RNA polymerase inhibitors.
AID310769Cytotoxicity against human CEM-SS cells upto 40 uM after 3 days2007Bioorganic & medicinal chemistry letters, Dec-15, Volume: 17, Issue:24
Syntheses of novel myxopyronin B analogs as potential inhibitors of bacterial RNA polymerase.
AID656620Antibacterial activity against Escherichia coli 1411 expressing lacI3, lacZ118, proB, trp, nalA, rpsL2011ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
Structure-based ligand design of novel bacterial RNA polymerase inhibitors.
AID757718Antibacterial activity against Escherichia coli expressing ToLC mutant assessed as growth inhibiiton after 18 hrs2013European journal of medicinal chemistry, Jul, Volume: 65Novel small molecule inhibitors targeting the "switch region" of bacterial RNAP: structure-based optimization of a virtual screening hit.
AID757715Antibacterial activity against Bacillus subtilis subsp. subtilis assessed as growth inhibiiton after 18 hrs2013European journal of medicinal chemistry, Jul, Volume: 65Novel small molecule inhibitors targeting the "switch region" of bacterial RNAP: structure-based optimization of a virtual screening hit.
AID656611Inhibition of Escherichia coli DNA dependent RNA polymerase assessed as inhibition of [14C]UTP incorporation after 15 mins by liquid scintillation counting2011ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
Structure-based ligand design of novel bacterial RNA polymerase inhibitors.
AID310765Antibacterial activity against Escherichia coli2007Bioorganic & medicinal chemistry letters, Dec-15, Volume: 17, Issue:24
Syntheses of novel myxopyronin B analogs as potential inhibitors of bacterial RNA polymerase.
AID310766Antibacterial activity against Escherichia coli Tol C mutant2007Bioorganic & medicinal chemistry letters, Dec-15, Volume: 17, Issue:24
Syntheses of novel myxopyronin B analogs as potential inhibitors of bacterial RNA polymerase.
AID776903Antibacterial activity against Escherichia coli expressing TolC mutant2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Discovery of novel bacterial RNA polymerase inhibitors: pharmacophore-based virtual screening and hit optimization.
AID757717Antibacterial activity against Escherichia coli K-12 assessed as growth inhibiiton after 18 hrs2013European journal of medicinal chemistry, Jul, Volume: 65Novel small molecule inhibitors targeting the "switch region" of bacterial RNAP: structure-based optimization of a virtual screening hit.
AID757722Inhibition of Escherichia coli RNAP assessed as incorporation of [5,6-3H]UTP preincubated for 10 mins followed by DNA template and ATP, CTP, GTP, UTP, [5,6-3H]UTP addition measured after 10 mins by scintillation counting analysis2013European journal of medicinal chemistry, Jul, Volume: 65Novel small molecule inhibitors targeting the "switch region" of bacterial RNAP: structure-based optimization of a virtual screening hit.
AID656614Inhibition of Escherichia coli DNA dependent RNA polymerase after 2 hrs by SYBR Green-based spectrophotometric analysis2011ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
Structure-based ligand design of novel bacterial RNA polymerase inhibitors.
AID656621Antibacterial activity against kanamycin-resistant,acrAB::Tn903 deficient Escherichia coli SM1411 expressing lacI3, lacZ118, proB, trp, nalA, rpsL2011ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
Structure-based ligand design of novel bacterial RNA polymerase inhibitors.
AID776906Inhibition of Escherichia coli RNA polymerase by transcription assay2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Discovery of novel bacterial RNA polymerase inhibitors: pharmacophore-based virtual screening and hit optimization.
AID757716Antibacterial activity against Pseudomonas aeruginosa PAO1 assessed as growth inhibiiton after 18 hrs2013European journal of medicinal chemistry, Jul, Volume: 65Novel small molecule inhibitors targeting the "switch region" of bacterial RNAP: structure-based optimization of a virtual screening hit.
AID656619Antibacterial activity against Bacillus subtilis 1S342011ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
Structure-based ligand design of novel bacterial RNA polymerase inhibitors.
AID776894Antibacterial activity against Staphylococcus aureus2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Discovery of novel bacterial RNA polymerase inhibitors: pharmacophore-based virtual screening and hit optimization.
AID310764Inhibition of Escherichia coli DNA-dependent RNA polymerase by nucleotide coupled NADPH/pyrophosphate release assay2007Bioorganic & medicinal chemistry letters, Dec-15, Volume: 17, Issue:24
Syntheses of novel myxopyronin B analogs as potential inhibitors of bacterial RNA polymerase.
AID656624Antibacterial activity against Escherichia coli 1411 expressing lacI3, lacZ118, proB, trp, nalA, rpsL in the presence of polymyxin B nonapeptide2011ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
Structure-based ligand design of novel bacterial RNA polymerase inhibitors.
AID656612Antibacterial activity against Staphylococcus aureus2011ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
Structure-based ligand design of novel bacterial RNA polymerase inhibitors.
AID757714Antibacterial activity against Staphylococcus aureus subsp. aureus Newman assessed as growth inhibiiton after 18 hrs2013European journal of medicinal chemistry, Jul, Volume: 65Novel small molecule inhibitors targeting the "switch region" of bacterial RNAP: structure-based optimization of a virtual screening hit.
AID776896Antibacterial activity against Escherichia coli K-122013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Discovery of novel bacterial RNA polymerase inhibitors: pharmacophore-based virtual screening and hit optimization.
AID776893Antibacterial activity against Bacillus subtilis2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Discovery of novel bacterial RNA polymerase inhibitors: pharmacophore-based virtual screening and hit optimization.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's4 (80.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
N-benzoylanthranilic acid
N-benzoylanthranilic acid : An amidobenzoic acid comprising benzoic acid having a benzamido group at the 2-position.		2.0810amidobenzoic acid
rifampin
Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)		2.7830cyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion		angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials